What “Cablivi patente” likely refers to
“Cablivi” is the brand name for caplacizumab, a medicine used for acquired thrombotic thrombocytopenic purpura (aTTP). When people ask “Cablivi patente,” they usually mean one of these:
- whether Cablivi is still under patent protection in a specific country, and when it expires
- whether there is a generic/biosimilar (or an equivalent) and when it can enter the market
- which company/filings hold the relevant patents
To answer precisely, I need the country/region (e.g., EU, UK, US, Brazil, India) and whether you mean original patents or market exclusivity (like supplementary protection / pediatric / data exclusivity).
When does Cablivi patent expire?
Patent expiry depends on:
- the jurisdiction (patent terms are country-specific)
- the specific patent family (not all patents on the product expire at the same time)
- whether there were patent term adjustments/ extensions or regulatory extensions
Without the country you mean, I can’t give a reliable expiration date.
Is caplacizumab generic or biosimilar?
Cablivi (caplacizumab) is a biologic, so market-entry competitors are typically biosimilar/biologic follow-on candidates rather than a small-molecule generic. Whether one can launch depends on:
- biosimilar development and regulatory approval status
- when the relevant patents/exclusivities expire in that country
If you tell me your country, I can map the typical patent/exclusivity pathway to that market.
Who owns Cablivi patents and where are they filed?
The patent owner(s) can vary by:
- the specific claims (drug substance, formulation, methods of use)
- country and assignee listed in patent registers
If you share the country, I can point you to what you’d look for in the patent registry and the likely categories of filings (composition, antibodies/epitopes, dosing/use in aTTP, manufacturing).
What details should you provide for an exact patent answer?
Reply with:
1) Country/region (EU/UK/US/etc.)
2) Whether you want the earliest likely expiry or a specific patent number/family
3) If you care about biosimilar entry timing or just patent expiration
Then I can give you a direct timeline and explain how it affects generic/biosimilar availability.
Sources
No sources were provided with your question, so I can’t cite patent dates or ownership accurately.